Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio
Interferon a (IFNa)
TLR7
TLR8
cytokine spectrum
imidazoquinoline
macrolide
pharmacokinetics
resiquimod
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
02
2023
accepted:
31
05
2023
medline:
7
7
2023
pubmed:
6
7
2023
entrez:
6
7
2023
Statut:
epublish
Résumé
TLR Agonists have promising activity in preclinical models of viral infection and cancer. However, clinical use is only in topical application. Systemic uses of TLR-ligands such as Resiquimod, have failed due to adverse effects that limited dose and thus, efficacy. This issue could be related to pharmacokinetic properties that include fast elimination leading to low AUC with simultaneously high c
Identifiants
pubmed: 37409123
doi: 10.3389/fimmu.2023.1168252
pmc: PMC10319141
doi:
Substances chimiques
Toll-Like Receptor 7
0
Tumor Necrosis Factor-alpha
0
Ligands
0
Interferon-alpha
0
Cytokines
0
Adjuvants, Immunologic
0
Macrolides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1168252Informations de copyright
Copyright © 2023 Keppler, Straß, Geiger, Fischer, Späth, Weinstein, Schwamborn, Guezguez, Guse, Laufer and Burnet.
Déclaration de conflit d'intérêts
Authors MK, SS, SG, TF, NS, TW, AS, JG, JHG, and MB were employed by the company Synovo GmbH. MK, SS, JHG, and MB are named as inventors in the corresponding patent. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Rev Drug Discov. 2019 Mar;18(3):219-234
pubmed: 30679806
Br J Cancer. 1996 Nov;74(9):1482-6
pubmed: 8912549
Nature. 2006 Jan 12;439(7073):204-7
pubmed: 16306937
Sci Signal. 2019 Oct 29;12(605):
pubmed: 31662487
Trends Microbiol. 2022 Feb;30(2):158-169
pubmed: 34253452
Front Immunol. 2019 Mar 29;10:325
pubmed: 30984161
Nat Rev Immunol. 2013 Jul;13(7):535-42
pubmed: 23743475
Oncogene. 2014 Jul 3;33(27):3485-95
pubmed: 23934186
Antimicrob Agents Chemother. 2008 Feb;52(2):477-82
pubmed: 18039918
Expert Opin Investig Drugs. 2013 Jan;22(1):149-59
pubmed: 23205468
Nat Biomed Eng. 2019 Apr;3(4):259-263
pubmed: 30952977
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817234
Ann Oncol. 2016 Aug;27(8):1625-32
pubmed: 27287206
Ther Drug Monit. 2006 Apr;28(2):219-25
pubmed: 16628134
J Clin Invest. 2020 Jul 1;130(7):3528-3542
pubmed: 32182225
J Exp Med. 2006 Aug 7;203(8):1999-2008
pubmed: 16864658
Nat Rev Immunol. 2008 Aug;8(8):594-606
pubmed: 18641647
Structure. 2011 Apr 13;19(4):447-59
pubmed: 21481769
Nature. 2006 Jan 12;439(7073):208-11
pubmed: 16306936
Antimicrob Agents Chemother. 2005 Jun;49(6):2372-7
pubmed: 15917536
Front Immunol. 2014 Sep 25;5:461
pubmed: 25309543
Cell. 2020 Mar 19;180(6):1044-1066
pubmed: 32164908
J Biol Chem. 2005 Apr 29;280(17):17005-12
pubmed: 15695821
Biol Pharm Bull. 2013;36(9):1494-9
pubmed: 23995662
Front Immunol. 2021 Oct 19;12:749190
pubmed: 34737750
Immunology. 2009 Feb;126(2):290-8
pubmed: 19019086
Nat Rev Drug Discov. 2018 Jan;17(1):35-56
pubmed: 28935918
Immunity. 2016 Oct 18;45(4):737-748
pubmed: 27742543
Drug Metab Dispos. 2008 Dec;36(12):2492-8
pubmed: 18755851
J Immunol. 2006 Nov 15;177(10):6584-7
pubmed: 17082568
Cancer Res. 2011 Aug 1;71(15):5123-33
pubmed: 21697281
Cells. 2022 Oct 06;11(19):
pubmed: 36231111
Nat Commun. 2019 Oct 15;10(1):4682
pubmed: 31615993
Nature. 2006 Apr 13;440(7086):949-53
pubmed: 16612387
Blood. 2011 May 26;117(21):5683-91
pubmed: 21487111
J Immunol. 2005 Feb 1;174(3):1259-68
pubmed: 15661881
Immunity. 2010 Mar 26;32(3):305-15
pubmed: 20346772
ChemMedChem. 2021 Jul 20;16(14):2254-2269
pubmed: 33787081
Sci Rep. 2017 Nov 29;7(1):16570
pubmed: 29185473
J Invest Dermatol. 2006 Jun;126(6):1338-47
pubmed: 16575388
Clin Exp Dermatol. 2002 Oct;27(7):571-7
pubmed: 12464152
Nature. 2005 Apr 21;434(7036):1035-40
pubmed: 15815647
Biopharm Drug Dispos. 2011 Oct;32(7):389-97
pubmed: 21812004
Nat Immunol. 2002 Jun;3(6):499
pubmed: 12032557
J Hepatol. 2007 Aug;47(2):174-82
pubmed: 17532523
J Med Chem. 2010 Jun 10;53(11):4450-65
pubmed: 20481492
Cell Mol Immunol. 2012 Nov;9(6):434-8
pubmed: 23085951
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Nat Immunol. 2002 Feb;3(2):196-200
pubmed: 11812998
Science. 2010 Sep 17;329(5998):1530-4
pubmed: 20847273
J Leukoc Biol. 2013 Jun;93(6):847-63
pubmed: 23475577
N Engl J Med. 2002 Sep 26;347(13):975-82
pubmed: 12324553
Science. 2013 Mar 22;339(6126):1426-9
pubmed: 23520111
Arch Toxicol. 2019 Jul;93(7):1917-1926
pubmed: 31111189
Nat Commun. 2021 Jul 16;12(1):4351
pubmed: 34272380
AAPS J. 2021 Mar 7;23(2):39
pubmed: 33677681
J Immunol. 2008 Mar 15;180(6):3729-38
pubmed: 18322178
Antimicrob Agents Chemother. 1989 Mar;33(3):277-82
pubmed: 2543276
J Neuroinflammation. 2016 May 09;13(1):102
pubmed: 27160148
Nat Rev Immunol. 2023 Feb;23(2):121-133
pubmed: 35672482
Cell Rep. 2018 Dec 18;25(12):3371-3381.e5
pubmed: 30566863
Semin Immunol. 2007 Feb;19(1):24-32
pubmed: 17275323
Front Pharmacol. 2017 May 31;8:304
pubmed: 28620298